학술논문
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia
Document Type
Article
Author
Source
In: Blood Advances . (Blood Advances, 23 January 2024, 8(2):378-387)
Subject
Language
English
ISSN
24739537
24739529
24739529